References
- Bhatia S, Robison L. In: Fisher DE, Look Orkin, AT, Lux SE, Ginsburg D, Nathan DG, eds. Oncology of Infancy and Chilhood. Vol. 1. CH. 1, Philadelphia (PA): Saunders Elsevier, 2009.
- Reiter AF, AA. In: Fisher DE, Look Orkin AT, Lux SE, Ginsburg D, Nathan DG, eds. Oncology of Infancy and Childhood. Vol. 1. Ch. 13, Philadelpha (PA): Saunders Elsevier, 2009.
- Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol. 2005;131(5):579–587. (2005). doi:10.1111/j.1365-2141.2005.05773.x.
- Scuto A, Kirschbaum M, Kowolik C, et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood. 2008;111(10):5093–5100. doi:10.1182/blood-2007-10-117762.
- Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31–39. doi:10.1182/blood-2006-06-025999.
- Fouladi M, Park JR, Stewart CF, et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children’s Oncology Group phase I consortium report. J Clin Oncol. 2010;28(22):3623–3629. doi:10.1200/JCO.2009.25.9119.
- Burke MJ, Lamba JK, Pounds S, et al. A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2014;89(9):889–895. doi:10.1002/ajh.23778.
- Burke MJ, Bhatla T. Epigenetic modifications in pediatric acute lymphoblastic leukemia. Front Pediatr. 2014;2:42. doi:10.3389/fped.2014.00042.
- Stubbs MC, Kim W, Bariteau M, et al. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. Clinical Cancer Research. 2015;21(10):2348–2358. doi:10.1158/1078-0432.CCR-14-1290.
- Khot A, Dickinson M, Prince HM. Panobinostat in lymphoid and myeloid malignancies. Expert Opin Invest Drugs . 2013;22(9):1211–1223. doi:10.1517/13543784.2013.815165.
- Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012;30(18):2197–2203. doi:10.1200/JCO.2011.38.1350.
- Burbury KL, Bishton MJ, Johnstone RW, et al. MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi). Ann Hematol. 2011;90(7):847–849. doi:10.1007/s00277-010-1099-6.
- Wood PJ, Strong R, McArthur GA, et al. A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors. Cancer Chemother Pharmacol. 2018;82(3):493–503. doi:10.1007/s00280-018-3634-4.
- Novartis. NDA 205353 FARYDAK (panobinostat) RISK EVALUATION AND MITIGATION STRATEGY (REMS) 2015.
- Tzogani K, Hennik PV, Walsh I, et al. EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma. The Oncol. 2018;23(7):870–870. doi:10.1634/theoncologist.2017-0301.
- DeAngelo DJ, Spencer A, Bhalla KN, et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia. 2013;27(8):1628–1636. doi:10.1038/leu.2013.38.
- Van Veggel M, Westerman E, Hamberg P. Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat. Clin Pharmacokinet. 2018;57(1):21–29. doi:10.1007/s40262-017-0565-x.
- Imai Y, Maru Y, Tanaka J. Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies. Cancer Sci. 2016;107(11):1543–1549. doi:10.1111/cas.13062.